View ValuationNephros 향후 성장Future 기준 점검 4/6Nephros은 연간 수입과 매출이 각각 23.5%와 10.9% 증가할 것으로 예상되고 EPS는 연간 15.9%만큼 증가할 것으로 예상됩니다.핵심 정보23.5%이익 성장률15.87%EPS 성장률Machinery 이익 성장24.9%매출 성장률10.9%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트18 May 2026최근 향후 성장 업데이트Breakeven Date Change • May 12Forecast to breakeven in 2025The analyst covering Nephros expects the company to break even for the first time. New forecast suggests losses will reduce by 68% to 2024. The company is expected to make a profit of US$538.0k in 2025. Average annual earnings growth of 121% is required to achieve expected profit on schedule.Breakeven Date Change • Dec 08Forecast to breakeven in 2025The 2 analysts covering Nephros expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 67% per year to 2024. The company is expected to make a profit of US$649.0k in 2025. Average annual earnings growth of 97% is required to achieve expected profit on schedule.모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Joe Harris was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • May 02Nephros, Inc. to Report Q1, 2026 Results on May 07, 2026Nephros, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026공시 • Apr 01Nephros Inc Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning ExpertiseNephros, Inc. announced an expansion of its customer-facing, water-safety support capabilities following the ASSE 12080 Legionella Water Safety and Management Specialist Certification earned by Brianne McGuire, Director of Business Development. The certification strengthens Nephros’ ability to provide consultative support to healthcare facilities and other complex buildings seeking to reduce waterborne pathogen risk and adds specific proficiency in the development of effective Water Management Programs (WMPs). This new capability marks a meaningful extension of Nephros’ field support for customers seeking more robust water safety programs. In addition to point-of-use filtration solutions, product installations and replacements, as well as public education, Nephros can now provide a direct Water Management Program development service. Water Management Programs offer a structured framework for identifying water-quality risks, establishing control measures, assigning responsibility, and defining ongoing monitoring and response. The company believes this offering will create additional value for customers while opening a new avenue for revenue generation through chargeable consulting service. Nephros considers this support expansion to be differentiated by the depth of practical knowledge informing it. Besides the new ASSE 12080 certification, Ms. McGuire brings broad experience in technical concerns, waterborne risk, current guidance and standards, and industry best practices born out of direct engagement with healthcare facilities and other regulated environments. Her leadership of the Nephros Water Institute and other company public education initiatives has further expanded the company’s perspective on how complex water safety risks are understood and addressed in practice. As a result, Nephros believes it is well-positioned to apply a diverse scope of understanding to the design of WMPs informed by extensive practical expertise in risk, implementation and real-world operational challenges.공시 • Mar 05Nephros, Inc. to Report Q4, 2025 Results on Mar 12, 2026Nephros, Inc. announced that they will report Q4, 2025 results After-Market on Mar 12, 2026공시 • Oct 31Nephros, Inc. to Report Q3, 2025 Results on Nov 06, 2025Nephros, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025공시 • Oct 09Nephros, Inc. Launches New Pfas Filter for Point-Of-Use Protection of Potable WaterNephros, Inc. announced the launch of its new filter designed to reduce Total PFAS, or per- and polyfluoroalkyl substances (PFAS), in potable water. This product expands Nephros' portfolio to address a category of chemical contaminants that have drawn growing regulatory and public health attention. PFAS, sometimes referred to as "forever chemicals," are synthetic compounds found in a wide range of consumer and industrial products. They are notable for their persistence in the environment, as well as their bioaccumulative nature and risk to human health. Key Features of the Nephros 19-Series PFAS Filter: Independently tested to NSF Standards 42 and 53; Validated reduction of Total PFAS, including PFOA and PFOS; Effectively reduces other hazardous contaminants such as lead, asbestos, cysts, chlorine, taste, and odor; 3,145-gallon capacity with a 1.63 GPM flow rate; Provides long-term protection against persistent, health-threatening waterborne contaminants.공시 • Aug 01Nephros, Inc. to Report Q2, 2025 Results on Aug 07, 2025Nephros, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025공시 • Jun 19Nephros, Inc. Approves Election of Lisa Nettis as DirectorNephros, Inc. announced at the AGM held on June 16, 2025, approved Lisa Nettis as director, to serve a three-year term expiring in 2028.공시 • May 01Nephros, Inc., Annual General Meeting, Jun 16, 2025Nephros, Inc., Annual General Meeting, Jun 16, 2025. Location: virtualshareholdermeeting.com/neph2025, United StatesReported Earnings • Nov 10Third quarter 2024 earnings released: EPS: US$0.017 (vs US$0.017 loss in 3Q 2023)Third quarter 2024 results: EPS: US$0.017 (up from US$0.017 loss in 3Q 2023). Revenue: US$3.52m (down 6.0% from 3Q 2023). Net income: US$183.0k (up US$365.0k from 3Q 2023). Profit margin: 5.2% (up from net loss in 3Q 2023). The move to profitability was driven by lower expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Machinery industry in Germany.공시 • Oct 31Nephros, Inc. to Report Q3, 2024 Results on Nov 07, 2024Nephros, Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024공시 • Oct 25Nephros, Inc. Launches New HydraGuard 20" UltraFilterNephros, Inc. announced the release of the HydraGuard 20" UltraFilter. This latest innovation enables the company to break into new markets and aid in compliance with water quality standards such as ANSI/AAMI ST108. The HydraGuard 20" model is an extension of the existing HydraGuard and designed to provide a higher-volume capacity and flow rate, while removing harmful contaminants like bacteria, viruses, and endotoxins. With this product, Nephros is poised to serve a broader range of customers, including companies within medical device manufacturing and pharmaceutical production, to ensure the highest level of water purity for industries that require strict quality standards. The HydraGuard 20" filter opens the door to expanded revenue opportunities and greater support for businesses and facilities struggling to establish or maintain compliance with strict regulatory standards. Most notably, the issuance of ANSI/AAMI ST 108 in late 2023 introduced new metrics for sterile processing, such as water testing schedules and parameters for bacteria and endotoxin presence. Solutions like the HydraGuard, along with other Nephros infection control products, provide exceptional retention of microbiological contaminants and support purification of water beyond the new standards. Regarding endotoxins specifically, Nephros in-line filters have the additional benefit of performance based on size exclusion, which achieves reliable and consistent retention compared to the more typical charged membranes.Reported Earnings • Aug 11Second quarter 2024 earnings released: US$0.027 loss per share (vs US$0.042 loss in 2Q 2023)Second quarter 2024 results: US$0.027 loss per share (improved from US$0.042 loss in 2Q 2023). Revenue: US$3.25m (down 8.3% from 2Q 2023). Net loss: US$289.0k (loss narrowed 33% from 2Q 2023). Revenue is forecast to grow 6.2% p.a. on average during the next 2 years, compared to a 4.5% growth forecast for the Machinery industry in Germany.공시 • Aug 01Nephros, Inc. to Report Q2, 2024 Results on Aug 08, 2024Nephros, Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024Recent Insider Transactions • May 17President recently bought €103k worth of stockOn the 16th of May, Robert Banks bought around 50k shares on-market at roughly €2.06 per share. This transaction increased Robert's direct individual holding by 3x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Robert has been a buyer over the last 12 months, purchasing a net total of €140k worth in shares.Reported Earnings • May 13First quarter 2024 earnings released: US$0.016 loss per share (vs US$0.03 loss in 1Q 2023)First quarter 2024 results: US$0.016 loss per share (improved from US$0.03 loss in 1Q 2023). Revenue: US$3.52m (down 4.7% from 1Q 2023). Net loss: US$169.0k (loss narrowed 45% from 1Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.1% growth forecast for the Consumer Durables industry in Germany.Breakeven Date Change • May 12Forecast to breakeven in 2025The analyst covering Nephros expects the company to break even for the first time. New forecast suggests losses will reduce by 68% to 2024. The company is expected to make a profit of US$538.0k in 2025. Average annual earnings growth of 121% is required to achieve expected profit on schedule.공시 • Apr 14Nephros, Inc., Annual General Meeting, May 23, 2024Nephros, Inc., Annual General Meeting, May 23, 2024, at 10:00 US Eastern Standard Time. Location: 380 Lackawanna Place South Orange New Jersey United States Agenda: to Elect two directors to serve a three-year term expiring in 2027; Ratify the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; Approve the 2024 Equity Incentive Plan; Approve the compensation of the Company’s named executive officers on an advisory (non-binding) basis; and Act upon such other matters as may properly come before the meeting or any adjournment thereof.Reported Earnings • Mar 10Full year 2023 earnings released: US$0.15 loss per share (vs US$0.44 loss in FY 2022)Full year 2023 results: US$0.15 loss per share (improved from US$0.44 loss in FY 2022). Revenue: US$14.2m (up 43% from FY 2022). Net loss: US$1.58m (loss narrowed 65% from FY 2022). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.7% growth forecast for the Consumer Durables industry in Germany.New Risk • Mar 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (€29.1m market cap, or US$31.8m).공시 • Mar 01Nephros, Inc. to Report Q4, 2023 Results on Mar 07, 2024Nephros, Inc. announced that they will report Q4, 2023 results After-Market on Mar 07, 2024Buy Or Sell Opportunity • Feb 05Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at €3.28. The fair value is estimated to be €4.27, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 22% in a year. Earnings are forecast to grow by 60% in the next year.Buying Opportunity • Jan 13Now 27% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €4.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 22% in a year. Earnings is forecast to grow by 60% in the next year.Buying Opportunity • Dec 27Now 23% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €3.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 22% in a year. Earnings is forecast to grow by 60% in the next year.Breakeven Date Change • Dec 08Forecast to breakeven in 2025The 2 analysts covering Nephros expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 67% per year to 2024. The company is expected to make a profit of US$649.0k in 2025. Average annual earnings growth of 97% is required to achieve expected profit on schedule.이익 및 매출 성장 예측DB:NPJP - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2027231N/AN/A112/31/2026211N/AN/A23/31/202619100N/A12/31/202519122N/A9/30/202518133N/A6/30/202517122N/A3/31/202516101N/A12/31/2024140-10N/A9/30/202414-1-2-2N/A6/30/202414-1-1-1N/A3/31/202414-100N/A12/31/202314-211N/A9/30/202314-211N/A6/30/202312-300N/A3/31/202312-3-1-1N/A12/31/202210-5-3-3N/A9/30/202210-5-4-3N/A6/30/202210-4-4-4N/A3/31/202210-4-3-3N/A12/31/202110-3-2-1N/A9/30/202110-3-3-3N/A6/30/20219-4-4-4N/A3/31/20219-4-5-5N/A12/31/20209-5-7-7N/A9/30/20209-4-5-5N/A6/30/202010-4-4-4N/A3/31/202011-3-3-3N/A12/31/201910-3N/A-2N/A9/30/20199-4N/A-3N/A6/30/20197-4N/A-4N/A3/31/20196-3N/A-4N/A12/31/20186-3N/A-4N/A9/30/20185-1N/A-1N/A6/30/20185-1N/A-1N/A3/31/20184-2N/A0N/A12/31/20174-1N/A0N/A9/30/20173-3N/A-2N/A6/30/20173-3N/A-2N/A3/31/20172-3N/A-2N/A12/31/20162-3N/A-2N/A9/30/20162-3N/A-3N/A6/30/20162-3N/A-3N/A3/31/20162-4N/A-3N/A12/31/20152-3N/A-4N/A9/30/20152-3N/A-3N/A6/30/201520N/A-3N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: NPJP 의 연간 예상 수익 증가율(23.5%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: NPJP 의 연간 수익(23.5%)이 German 시장(17.2%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: NPJP 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: NPJP 의 수익(연간 10.9%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: NPJP 의 수익(연간 10.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: NPJP의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YCapital-goods 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 00:21종가2026/05/27 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Nephros, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Robert WassermanBenchmark CompanyMarc WiesenbergerB. Riley Securities, Inc.Anthony VendettiMaxim Group
Breakeven Date Change • May 12Forecast to breakeven in 2025The analyst covering Nephros expects the company to break even for the first time. New forecast suggests losses will reduce by 68% to 2024. The company is expected to make a profit of US$538.0k in 2025. Average annual earnings growth of 121% is required to achieve expected profit on schedule.
Breakeven Date Change • Dec 08Forecast to breakeven in 2025The 2 analysts covering Nephros expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 67% per year to 2024. The company is expected to make a profit of US$649.0k in 2025. Average annual earnings growth of 97% is required to achieve expected profit on schedule.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Joe Harris was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • May 02Nephros, Inc. to Report Q1, 2026 Results on May 07, 2026Nephros, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026
공시 • Apr 01Nephros Inc Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning ExpertiseNephros, Inc. announced an expansion of its customer-facing, water-safety support capabilities following the ASSE 12080 Legionella Water Safety and Management Specialist Certification earned by Brianne McGuire, Director of Business Development. The certification strengthens Nephros’ ability to provide consultative support to healthcare facilities and other complex buildings seeking to reduce waterborne pathogen risk and adds specific proficiency in the development of effective Water Management Programs (WMPs). This new capability marks a meaningful extension of Nephros’ field support for customers seeking more robust water safety programs. In addition to point-of-use filtration solutions, product installations and replacements, as well as public education, Nephros can now provide a direct Water Management Program development service. Water Management Programs offer a structured framework for identifying water-quality risks, establishing control measures, assigning responsibility, and defining ongoing monitoring and response. The company believes this offering will create additional value for customers while opening a new avenue for revenue generation through chargeable consulting service. Nephros considers this support expansion to be differentiated by the depth of practical knowledge informing it. Besides the new ASSE 12080 certification, Ms. McGuire brings broad experience in technical concerns, waterborne risk, current guidance and standards, and industry best practices born out of direct engagement with healthcare facilities and other regulated environments. Her leadership of the Nephros Water Institute and other company public education initiatives has further expanded the company’s perspective on how complex water safety risks are understood and addressed in practice. As a result, Nephros believes it is well-positioned to apply a diverse scope of understanding to the design of WMPs informed by extensive practical expertise in risk, implementation and real-world operational challenges.
공시 • Mar 05Nephros, Inc. to Report Q4, 2025 Results on Mar 12, 2026Nephros, Inc. announced that they will report Q4, 2025 results After-Market on Mar 12, 2026
공시 • Oct 31Nephros, Inc. to Report Q3, 2025 Results on Nov 06, 2025Nephros, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025
공시 • Oct 09Nephros, Inc. Launches New Pfas Filter for Point-Of-Use Protection of Potable WaterNephros, Inc. announced the launch of its new filter designed to reduce Total PFAS, or per- and polyfluoroalkyl substances (PFAS), in potable water. This product expands Nephros' portfolio to address a category of chemical contaminants that have drawn growing regulatory and public health attention. PFAS, sometimes referred to as "forever chemicals," are synthetic compounds found in a wide range of consumer and industrial products. They are notable for their persistence in the environment, as well as their bioaccumulative nature and risk to human health. Key Features of the Nephros 19-Series PFAS Filter: Independently tested to NSF Standards 42 and 53; Validated reduction of Total PFAS, including PFOA and PFOS; Effectively reduces other hazardous contaminants such as lead, asbestos, cysts, chlorine, taste, and odor; 3,145-gallon capacity with a 1.63 GPM flow rate; Provides long-term protection against persistent, health-threatening waterborne contaminants.
공시 • Aug 01Nephros, Inc. to Report Q2, 2025 Results on Aug 07, 2025Nephros, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025
공시 • Jun 19Nephros, Inc. Approves Election of Lisa Nettis as DirectorNephros, Inc. announced at the AGM held on June 16, 2025, approved Lisa Nettis as director, to serve a three-year term expiring in 2028.
공시 • May 01Nephros, Inc., Annual General Meeting, Jun 16, 2025Nephros, Inc., Annual General Meeting, Jun 16, 2025. Location: virtualshareholdermeeting.com/neph2025, United States
Reported Earnings • Nov 10Third quarter 2024 earnings released: EPS: US$0.017 (vs US$0.017 loss in 3Q 2023)Third quarter 2024 results: EPS: US$0.017 (up from US$0.017 loss in 3Q 2023). Revenue: US$3.52m (down 6.0% from 3Q 2023). Net income: US$183.0k (up US$365.0k from 3Q 2023). Profit margin: 5.2% (up from net loss in 3Q 2023). The move to profitability was driven by lower expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Machinery industry in Germany.
공시 • Oct 31Nephros, Inc. to Report Q3, 2024 Results on Nov 07, 2024Nephros, Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024
공시 • Oct 25Nephros, Inc. Launches New HydraGuard 20" UltraFilterNephros, Inc. announced the release of the HydraGuard 20" UltraFilter. This latest innovation enables the company to break into new markets and aid in compliance with water quality standards such as ANSI/AAMI ST108. The HydraGuard 20" model is an extension of the existing HydraGuard and designed to provide a higher-volume capacity and flow rate, while removing harmful contaminants like bacteria, viruses, and endotoxins. With this product, Nephros is poised to serve a broader range of customers, including companies within medical device manufacturing and pharmaceutical production, to ensure the highest level of water purity for industries that require strict quality standards. The HydraGuard 20" filter opens the door to expanded revenue opportunities and greater support for businesses and facilities struggling to establish or maintain compliance with strict regulatory standards. Most notably, the issuance of ANSI/AAMI ST 108 in late 2023 introduced new metrics for sterile processing, such as water testing schedules and parameters for bacteria and endotoxin presence. Solutions like the HydraGuard, along with other Nephros infection control products, provide exceptional retention of microbiological contaminants and support purification of water beyond the new standards. Regarding endotoxins specifically, Nephros in-line filters have the additional benefit of performance based on size exclusion, which achieves reliable and consistent retention compared to the more typical charged membranes.
Reported Earnings • Aug 11Second quarter 2024 earnings released: US$0.027 loss per share (vs US$0.042 loss in 2Q 2023)Second quarter 2024 results: US$0.027 loss per share (improved from US$0.042 loss in 2Q 2023). Revenue: US$3.25m (down 8.3% from 2Q 2023). Net loss: US$289.0k (loss narrowed 33% from 2Q 2023). Revenue is forecast to grow 6.2% p.a. on average during the next 2 years, compared to a 4.5% growth forecast for the Machinery industry in Germany.
공시 • Aug 01Nephros, Inc. to Report Q2, 2024 Results on Aug 08, 2024Nephros, Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024
Recent Insider Transactions • May 17President recently bought €103k worth of stockOn the 16th of May, Robert Banks bought around 50k shares on-market at roughly €2.06 per share. This transaction increased Robert's direct individual holding by 3x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Robert has been a buyer over the last 12 months, purchasing a net total of €140k worth in shares.
Reported Earnings • May 13First quarter 2024 earnings released: US$0.016 loss per share (vs US$0.03 loss in 1Q 2023)First quarter 2024 results: US$0.016 loss per share (improved from US$0.03 loss in 1Q 2023). Revenue: US$3.52m (down 4.7% from 1Q 2023). Net loss: US$169.0k (loss narrowed 45% from 1Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.1% growth forecast for the Consumer Durables industry in Germany.
Breakeven Date Change • May 12Forecast to breakeven in 2025The analyst covering Nephros expects the company to break even for the first time. New forecast suggests losses will reduce by 68% to 2024. The company is expected to make a profit of US$538.0k in 2025. Average annual earnings growth of 121% is required to achieve expected profit on schedule.
공시 • Apr 14Nephros, Inc., Annual General Meeting, May 23, 2024Nephros, Inc., Annual General Meeting, May 23, 2024, at 10:00 US Eastern Standard Time. Location: 380 Lackawanna Place South Orange New Jersey United States Agenda: to Elect two directors to serve a three-year term expiring in 2027; Ratify the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; Approve the 2024 Equity Incentive Plan; Approve the compensation of the Company’s named executive officers on an advisory (non-binding) basis; and Act upon such other matters as may properly come before the meeting or any adjournment thereof.
Reported Earnings • Mar 10Full year 2023 earnings released: US$0.15 loss per share (vs US$0.44 loss in FY 2022)Full year 2023 results: US$0.15 loss per share (improved from US$0.44 loss in FY 2022). Revenue: US$14.2m (up 43% from FY 2022). Net loss: US$1.58m (loss narrowed 65% from FY 2022). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.7% growth forecast for the Consumer Durables industry in Germany.
New Risk • Mar 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (€29.1m market cap, or US$31.8m).
공시 • Mar 01Nephros, Inc. to Report Q4, 2023 Results on Mar 07, 2024Nephros, Inc. announced that they will report Q4, 2023 results After-Market on Mar 07, 2024
Buy Or Sell Opportunity • Feb 05Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at €3.28. The fair value is estimated to be €4.27, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 22% in a year. Earnings are forecast to grow by 60% in the next year.
Buying Opportunity • Jan 13Now 27% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €4.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 22% in a year. Earnings is forecast to grow by 60% in the next year.
Buying Opportunity • Dec 27Now 23% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €3.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 22% in a year. Earnings is forecast to grow by 60% in the next year.
Breakeven Date Change • Dec 08Forecast to breakeven in 2025The 2 analysts covering Nephros expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 67% per year to 2024. The company is expected to make a profit of US$649.0k in 2025. Average annual earnings growth of 97% is required to achieve expected profit on schedule.